Clinical Trials Logo

Dialysis; Complications clinical trials

View clinical trials related to Dialysis; Complications.

Filter by:

NCT ID: NCT06446739 Not yet recruiting - Acute Kidney Injury Clinical Trials

LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)

WISDOM
Start date: June 2024
Phase: N/A
Study type: Interventional

An estimated 10-15% of critically ill patients with acute kidney failure in the intensive care unit receive acute dialysis therapy. The majority of these patients initially receive continuous for of dialysis therapy call continuous renal replacement therapy (CRRT). Prior studies have suggested that higher CRRT dose-intensity improved health outcomes for these patients; however, this was not found in high-quality clinical trials. These more recent trials suggested a lower range of dose-intensity compared with the higher range as the new standard of care. This was incorporated into guidelines. To date, no clinical trials have evaluated this lower range and specifically, it is plausible that an even lower dose-intensity of CRRT may be well tolerated, safe, associated with similar outcomes and be more cost-effective. This is the objective of the WISDOM trial, to compare the guideline standard with lower dose-intensity among patients who are started on CRRT in the intensive care unit.

NCT ID: NCT06412770 Not yet recruiting - Quality of Life Clinical Trials

Effect of Tai Chi on Symptoms in Hemodialysis Patients

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the effect of Tai Chi on symptoms in hemodialysis patients.The main question[s] it aims to answer are: the effect of Tai Chi on symptoms or the quality of life in hemodialysis patients .Participants will be divided into three groups, one group will be asked to do Tai Chi for 30 minutes three times a week, and the other group will be asked to do Tai Chi imagery for 30 minutes three times a week. The comparison group will be given usual care. Researchers will compare the efficacy of symptoms and quality of life in dialysis patients in each group.

NCT ID: NCT06374537 Recruiting - Frailty Clinical Trials

Evaluate the Impact of Targeted Physical Activity on Clinically Debilitated Dialysis Patients.

Start date: May 22, 2019
Phase: N/A
Study type: Interventional

This research is being done to better understand the impact of the use of a specific physical activity training program (GH Method) in dialysis/kidney disease patients.

NCT ID: NCT06360302 Not yet recruiting - Metabolic Syndrome Clinical Trials

Plasma Biomarkers of Muscle Metabolism During Exercise to the Assessment of Insulin Resistance in CKD Dialysis Patients

KREBSome-IRC
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

This prospective, multicenter, cross-sectional, repeated-measures comparative study compared functional and biochemical response profiles to exercise between 2 groups of chronically ill patients (chronic renal failure dialysis patients and patients with metabolic syndrome) and a group of healthy subjects. The hypothesis is that the addition of plasma metabolic intermediates associated with energy disorders linked to insulin resistance, will improve the sensitivity of the assessment of muscle oxidative metabolism abnormalities, as reported in exercise intolerant subjects. In this way, the metabolomics approach during exercise would provide a biological and functional "signature" of insulin resistance of muscular origin, discriminating between insulin-resistant patients, healthy control subjects and dialysis patients, with an exercise metabolic profile approaching that observed in insulin-resistant patients. A better understanding of metabolic abnormalities could guide muscle rehabilitation. Participants will be asked to perform an exercise test, with several blood samples taken at different exercise intensities. Researchers will compare the metabolic profile of three groups: patients with chronic kidney disease, patients with metabolic syndrome and healthy subjects: - V'O2-adjusted lactate at rest and during exercise - The combination of exercise energy metabolism intermediates reflecting insulin resistance among Krebs cycle cofactors/substrates, ß-oxidation cofactors/substrates, amino acids

NCT ID: NCT06242041 Recruiting - Cardiac Arrhythmia Clinical Trials

The Effect of Potassium Lowering Drugs on Cardiac Electrical Stability in Hemodialysis Patients (ART Study)

Start date: February 14, 2022
Phase: Phase 4
Study type: Interventional

This study is a multicenter, prospective and randomized controlled study. The experiment includes a 1-week screening period (1 week before dialysis) and a 7-week treatment period (1-4 weeks of dose drip period and 5-7 weeks of evaluation period). During the screening period, all patients were randomly divided into the control group and the treatment group. On the non-dialysis day of the treatment period, the treatment group was given a certain dose of sodium zirconium silicate, and the blood potassium value was measured before and after each dialysis to maintain the blood potassium at 4.0-5.0mmol/L before dialysis. At the same time, 12-lead ECG and 24-hour Holter were completed at the first and last dialysis during the treatment period, and finally the ECG stability and its relationship with blood potassium were evaluated.

NCT ID: NCT06213129 Not yet recruiting - Clinical trials for Dialysis; Complications

Effect of Sodium and UF Profiling on Dialysis

Start date: January 15, 2024
Phase:
Study type: Observational

The aim of this study is to evaluate the effects of sodium and UF profiling on hemodynamic stability, interdialytic weight gain, and intradialytic complications

NCT ID: NCT06153888 Recruiting - Fluid Overload Clinical Trials

ULtrafiltration-Rate Induced CArdiac Strain (ULRICA) - Study

ULRICA
Start date: March 20, 2023
Phase: N/A
Study type: Interventional

Patients performing chronic hemodialysis (HD) retain more or less water between dialyses. The water is removed by ultrafiltration and usually during the cleansing of waste products - the HD. The length of HD is usually the same as the time of fluid removal while sometimes this may differ. There is no clear guideline. In previous research the investigator noted that the heart releases more NT-pro-BNP during HD in numerous of the patients. The present study aims to clarify if the speed of fluid removal during HD is a factor that may alter the release of cardiac markers during HD. If so the recommendations for the prescription of HD can be updated.

NCT ID: NCT06141798 Recruiting - Quality of Life Clinical Trials

Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients

Start date: November 23, 2021
Phase: N/A
Study type: Interventional

As Korea is becoming a super-aged society, the number of elderly patients with end-stage kidney disease (ESKD) is expected to increase rapidly. Therefore, the burden on Korean society will also increase. Thrice-weekly hemodialysis is standard for renal replacement therapy. However, this regimen has not been validated for elderly ESKD patients with residual renal function. Elderly patients can have multiple comorbidities such as hypertension, diabetes, cardiovascular disease, and impaired physical activity. Frequent hemodialysis could provoke falls, hypotension, and cognitive impairment. Previous reports have suggested the potential benefit of twice-weekly hemodialysis with incremental increases in frequency when residual renal function decreases. In addition, twice-weekly hemodialysis decreases hospitalization rates in frail patients. Therefore, the investigators hypothesized initiating renal replacement therapy with twice-weekly hemodialysis decreases the hopsitalizatoin rates compared with conventional thrice-weekly hemodialysis in elderly ESRD patients with residual renal function. This study is a pragmatic randomized clinical trial, multicenter study. Study subjects are incident ESRD patients (>= 60 years old, n=428) with residual urine volume ( > 500 mL/day) and follow up up to 2 years. Twice-weekly hemodialysis could be incremented according to clinical situations such as volume overload, hyperkalemia and uremic symptom. Primary outcome of this study is hospitalization rate during follow-up. Secondary outcomes include dialysis related hospitalization rate, the length of hospital stay, complication of dialysis,mortality rate and assessments of quality of life, frailty, and cost-utility.

NCT ID: NCT06123806 Not yet recruiting - Clinical trials for Dialysis; Complications

Factors Affecting Dialysis Associated Fatigue

Start date: June 2024
Phase:
Study type: Observational

The aim of this study is to investigate the factors affecting hemodialysis-associated fatigue and their impact on the physical and emotional well-being of patients. By identifying these factors, Investigators can develop effective strategies to reduce fatigue and enhance the overall quality of life for hemodialysis patients.

NCT ID: NCT06022835 Completed - Clinical trials for End Stage Renal Disease on Dialysis

Chlorhexidine Gluconate-gel Dressing for Exit Site Infection in Peritoneal Dialysis

Start date: September 27, 2019
Phase: N/A
Study type: Interventional

Exit site infection (ESI) is one of the major predisposing factors to peritoneal dialysis (PD) related peritonitis. Chlorhexidine Gluconate (CHG) has been widely used for cutaneous disinfection for half a century. TegadermTM CHG is a water-proof dressing with gel pads that provide 2% CHG to the skin surface and effectively prevents catheter-related infections for intravascular catheters. However, its use has not been accessed in patients with PD catheters. We aim to evaluate the effectiveness of TegadermTM CHG dressing in preventing ESI in PD patients.